Oxford Biomedica and Microsoft Research announced a R&D collaboration that aims to use cloud and machine learning to improve the purity and yield of next-gen cell- and gene-delivery technology. The partnership will focus on developing new technologies for next-generation cell therapies using gene therapy or other approaches in which cells are genetically modified with genes from another species.
Oxford Biomedica and Microsoft Research announced a R&D collaboration that aims to use cloud and machine learning to improve the purity and yield of next-gen cell- and gene-delivery technology. Combining the companies’ technologies is expected to help Oxford Biomedica - which is also working with Synthace to further hone manufacturing process design, simulation and execution – both to develop new treatments and increase the cost effectiveness of existing ones.